Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | TCF4 | P15884 | 2/20 | 0.65 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.52 |
| ▸ | PFKFB4 | Q16877 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582937 | 1.00 | POLB (1.00) | POLBSMN1; SMN2ALDH1A1TCF4CTNNB1 | |
| SCHEMBL27621260 | 0.87 | POLB (0.77) | POLBSMN1; SMN2ALDH1A1TCF4CTNNB1 | |
| SCHEMBL3560486 | 0.84 | POLB (0.73) | POLBSMN1; SMN2ALDH1A1RAB9AKDM4E | |
| SCHEMBL4187307 | 0.84 | POLB (0.72) | POLBSMN1; SMN2ALDH1A1TCF4CTNNB1 | |
| SCHEMBL27182994 | 0.84 | POLB (0.72) | POLBSMN1; SMN2ALDH1A1TCF4CTNNB1 | |
| Hydrazine SCHEMBL28783394 | 0.84 | POLB (0.72) | POLBSMN1; SMN2ALDH1A1TCF4CTNNB1 | |
| SCHEMBL13485182 | 0.83 | POLB (0.71) | POLBSMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29522198 | 0.83 | ALDH1A1 (0.75) | POLBSMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL1677059 | 0.83 | ALDH1A1 (0.75) | POLBSMN1; SMN2ALDH1A1NPC1HPGD | |
| SCHEMBL334530 | 0.83 | ALDH1A1 (1.00) | POLBSMN1; SMN2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-1651640-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651641-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1611089-A2 | HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005033115-A1 | NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO[4,5-D] PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | WO | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005009994-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004080376-A2 | HYDROXYETHYLAMINE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY FOR THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | POLB 4265/4885SMN1; SMN2 3369/4885ALDH1A1 2876/4885 |
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | POLB 1310/4885SMN1; SMN2 2287/4885ALDH1A1 212/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | POLB 4356/4885SMN1; SMN2 3245/4885ALDH1A1 3454/4885 |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | POLB 3920/4885SMN1; SMN2 3500/4885ALDH1A1 4548/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | POLB 4498/4885SMN1; SMN2 2652/4885ALDH1A1 3269/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | POLB 2978/4885SMN1; SMN2 2370/4885ALDH1A1 3506/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | POLB 4332/4885SMN1; SMN2 3886/4885ALDH1A1 4035/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | POLB 3295/4885SMN1; SMN2 2293/4885ALDH1A1 2966/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | POLB 4265/4885SMN1; SMN2 3369/4885ALDH1A1 2876/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | POLB 1310/4885SMN1; SMN2 2287/4885ALDH1A1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.